TS-1 combination OD tablet specific use-results survey "To evaluate safety of tegafur, gimeracil, oteracil potassium combination OD tablet"

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080222542

Enrollment

1000

Registered

2014-06-26

Start date

2014-06-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

investigational material(s) Generic name etc : TS-1 combination OD tablet T20/T25 INN of investigational material : TS-1 (tegafur + gimeracil + oteracil potassium) Therapeutic category code : 422 Anti

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically proven gastric cancer 2. Residual tumor R0 or R1 after surgery 3. Started chemotherapy within 6 weeks after surgery 4. No previous treatment for cancer except for the initial gastric resection for the primary lesion 5. No multiple primary cancer or multicentric cancer 6. No serious postoperative complication 7. Informed consent for treatment

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Frequency of adverse drug reactions (until 1 year after surgery) The frequency of adverse events will be tabulated by type, seriousness, causal relationship, time of onset, etc.	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026